A New Approach to Respiratory Protection
Most treatments for respiratory infections work after you are already sick. N001 is designed to act before infection takes hold. At the moment of first contact, in the place where viruses first enter the body.
Respiratory Viruses Start in One Place
When you breathe in a respiratory virus, it enters through your nose and upper airway. This is where infection begins, and where the body's first defences are activated. If the virus is not stopped here, it can replicate, spread deeper into the lungs, and lead to more serious illness.
Most treatments are designed to help after infection has already progressed. The window to act at the very beginning, at the point of entry, has largely gone unaddressed.
Designed to Act at the Point of Entry
N001 is being developed to deliver protection directly to the upper airway. Rather than targeting a specific virus, N001 is designed to support your body's own natural defences at the moment they are needed most.
It is intended for use before exposure or shortly after, not as a treatment once symptoms have already begun.
Self-administered.
Simple to Use.
N001 is a nasal spray. It requires no injection and no clinical visit. N001 is self-administered and simple to use across all populations. This makes it deployable at the scale that an effective response to respiratory viruses demands. Designed to be accessible wherever it is needed, regardless of setting or geography.
The Earlier the Response, the Better the Opportunity
Research has shown that what happens in the first hours of a respiratory infection can shape how the illness develops. Early activity at the site of entry may reduce how much virus is present, how far it spreads, and how severe the illness becomes.
This is the window N001 is designed to address. Not after illness is established, but before it has the chance to progress.
Development Status & FAQ
N001 is not yet available. Ness Therapeutics Inc. is currently in active discussions with Health Canada as we work through the requirements needed to bring N001 to market. We are committed to following the rigorous and established path used to bring life-changing medicines to patients.
Not yet. N001 is still in development and is not currently available. We are working through the steps required to bring it to market responsibly.
N001 is being developed for people who want protection against respiratory viruses before they get sick.
N001 is designed to work broadly across respiratory viruses rather than targeting one specific virus. This means it is not built around a single pathogen, making it relevant across a wide range of respiratory virus threats.
No. N001 is a nasal spray designed to support your body's natural defences at the point where viruses first enter.
Yes. Ness Therapeutics Inc. is a Canadian company and N001 is being developed in Canada. Ness Therapeutics Inc. has received funding from the Government of Canada and is partnered with the National Research Council of Canada in support of its development program.
Have a question? Get in Touch.
Want to Follow the Progress of N001?
Ness Therapeutics Inc. is making steady progress on N001 and we are committed to sharing updates every step of the way. Sign up to receive the latest news on our program advances.
